{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:58Z","timestamp":1794047518703,"version":"4.8.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.biopha.2022.112684","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T06:51:48Z","timestamp":1644303108000},"page":"112684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant women"],"prefix":"10.1016","volume":"148","author":[{"given":"Britt I.","family":"Dr\u00f6gem\u00f6ller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galen E.B.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Trueman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Staub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fudan","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Higginson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella S.S.","family":"Groeneweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Magee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon D.","family":"Whyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia M.","family":"Brodie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert \u2019t","family":"Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Israels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrad R.","family":"Rassekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhayan","family":"Sanatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin J.D.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce C.","family":"Carleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.112684_bib1","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa032196","article-title":"A factorial trial of six interventions for the prevention of postoperative nausea and vomiting","volume":"350","author":"Apfel","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.112684_bib2","first-page":"e171","article-title":"Quantifying the global rates of nausea and vomiting of pregnancy: a meta analysis","volume":"20","author":"Einarson","year":"2013","journal-title":"J. Popul. Ther. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112684_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27584","article-title":"Risk factors for chemotherapy-induced nausea in pediatric patients receiving highly emetogenic chemotherapy","volume":"66","author":"Dupuis","year":"2019","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.biopha.2022.112684_bib4","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/ajhp\/56.8.729","article-title":"ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery","volume":"56","author":"DCS","year":"1999","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.biopha.2022.112684_bib5","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: American society of clinical oncology clinical practice guideline update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2022.112684_bib6","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/pbc.25063","article-title":"Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients","volume":"61","author":"Dupuis","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.biopha.2022.112684_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/FPC.0000000000000369","article-title":"PharmGKB summary: ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics","volume":"29","author":"Huddart","year":"2019","journal-title":"Pharmacogenet. Genom."},{"key":"10.1016\/j.biopha.2022.112684_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.reprotox.2019.03.001","article-title":"Use of ondansetron during pregnancy and the risk of major congenital malformations: a systematic review and meta-analysis","volume":"86","author":"Kaplan","year":"2019","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.biopha.2022.112684_bib9","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1056\/NEJMoa1211035","article-title":"Ondansetron in pregnancy and risk of adverse fetal outcomes","volume":"368","author":"Pasternak","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.112684_bib10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41572-019-0110-3","article-title":"Nausea and vomiting of pregnancy and hyperemesis gravidarum","volume":"5","author":"Fejzo","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.biopha.2022.112684_bib11","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1097\/PCC.0000000000000776","article-title":"Effect of ondansetron on QT interval in patients cared for in the PICU","volume":"17","author":"Trivedi","year":"2016","journal-title":"Pediatr. Crit. Care Med."},{"key":"10.1016\/j.biopha.2022.112684_bib12","unstructured":"GlaxoSmithKline, ZOFRAN (Product Monograph) Mississauga, Ontario, Canada, 2012."},{"key":"10.1016\/j.biopha.2022.112684_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/cpt.598","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron","volume":"102","author":"Bell","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.112684_bib14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0090-9556(25)08368-0","article-title":"The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron","volume":"22","author":"Fischer","year":"1994","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biopha.2022.112684_bib15","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/jcph.322","article-title":"Integration of modeling and simulation to support changes to ondansetron dosing following a randomized, double-blind, placebo-, and active-controlled thorough QT study","volume":"54","author":"Zuo","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112684_bib16","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/pds.1772","article-title":"Adverse drug reaction active surveillance: developing a national network in Canada\u2019s children\u2019s hospitals","volume":"18","author":"Carleton","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.biopha.2022.112684_bib17","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.hrthm.2008.03.037","article-title":"Accurate electrocardiographic assessment of the QT interval: teach the tangent","volume":"5","author":"Postema","year":"2008","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.biopha.2022.112684_bib18","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1460-9592.2010.03408.x","article-title":"The effects of droperidol and ondansetron on dispersion of myocardial repolarization in children","volume":"20","author":"Mehta","year":"2010","journal-title":"Paediatr. Anaesth."},{"key":"10.1016\/j.biopha.2022.112684_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/PEC.0000000000000757","article-title":"Effect of intravenous ondansetron on the QT interval of patients\u2019 electrocardiograms","volume":"34","author":"Krammes","year":"2018","journal-title":"Pediatr. Emerg. Care"},{"key":"10.1016\/j.biopha.2022.112684_bib20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1540-8167.2006.00408.x","article-title":"QT interval: how to measure it and what is \u201cnormal\u201d","volume":"17","author":"Goldenberg","year":"2006","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"10.1016\/j.biopha.2022.112684_bib21","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2010.01.001","article-title":"Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"55","author":"Drew","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.112684_bib22","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/s41588-018-0168-y","article-title":"Common variation near IRF6 is associated with IFN-beta-induced liver injury in multiple sclerosis","volume":"50","author":"Kowalec","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.biopha.2022.112684_bib23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/sj.clpt.6100033","article-title":"Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events","volume":"81","author":"Gaedigk","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.112684_bib24","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","article-title":"The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype","volume":"83","author":"Gaedigk","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2022.112684_bib25","unstructured":"PharmGKB, \u3008https:\/\/www.pharmgkb.org\/\u3009."},{"key":"10.1016\/j.biopha.2022.112684_bib26","unstructured":"NHGRI-EBI GWAS Catalogue, \u3008https:\/\/www.ebi.ac.uk\/gwas\/\u3009."},{"key":"10.1016\/j.biopha.2022.112684_bib27","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/tpj.2015.47","article-title":"Pharmacogenomic variants have larger effect sizes than genetic variants associated with other dichotomous complex traits","volume":"16","author":"Maranville","year":"2016","journal-title":"Pharmcogenom. J."},{"key":"10.1016\/j.biopha.2022.112684_bib28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrg2779","article-title":"Uncovering the roles of rare variants in common disease through whole-genome sequencing","volume":"11","author":"Cirulli","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.biopha.2022.112684_bib29","unstructured":"Flockhart Table\u2122, \u3008https:\/\/edswi.org\/wp-content\/uploads\/2018\/02\/Flockhart-Table-Medication-Metabolism.pdf\u3009."},{"key":"10.1016\/j.biopha.2022.112684_bib30","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2174\/1389200215666140202215316","article-title":"Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization","volume":"15","author":"Hicks","year":"2014","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.biopha.2022.112684_bib31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1472-8206.2002.00083.x","article-title":"Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity","volume":"16","author":"Shah","year":"2002","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112684_bib32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1472-8206.2002.00082.x","article-title":"Drug-induced prolongation of the QT interval: why the regulatory concern?","volume":"16","author":"Shah","year":"2002","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2022.112684_bib33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000339057","article-title":"Toll-like receptor 3 activation affects serotonin transporter activity and expression in human enterocyte-like Caco-2 cells","volume":"30","author":"Mendoza","year":"2012","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.biopha.2022.112684_bib34","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/acer.12410","article-title":"Ondansetron reduces naturalistic drinking in nontreatment-seeking alcohol-dependent individuals with the LL 5\u2032-HTTLPR genotype: a laboratory study","volume":"38","author":"Kenna","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.biopha.2022.112684_bib35","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.alcohol.2014.04.005","article-title":"Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: exploratory findings","volume":"48","author":"Kenna","year":"2014","journal-title":"Alcohol"},{"key":"10.1016\/j.biopha.2022.112684_bib36","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1530-0277.2008.00835.x","article-title":"A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline","volume":"33","author":"Kenna","year":"2009","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.biopha.2022.112684_bib37","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1176\/appi.ajp.2013.12091163","article-title":"Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron","volume":"170","author":"Johnson","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.biopha.2022.112684_bib38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1176\/appi.ajp.2010.10050755","article-title":"Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking","volume":"168","author":"Johnson","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.biopha.2022.112684_bib39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fpsyt.2012.00023","article-title":"Serotonin transporter genomic biomarker for quantitative assessment of ondansetron treatment response in alcoholics","volume":"3","author":"Seneviratne","year":"2012","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.biopha.2022.112684_bib40","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/mp.2010.94","article-title":"Functional genetic variants that increase synaptic serotonin and 5-HT3 receptor sensitivity predict alcohol and drug dependence","volume":"16","author":"Enoch","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.biopha.2022.112684_bib41","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200645040-00006","article-title":"Placental transfer of ondansetron during early human pregnancy","volume":"45","author":"Siu","year":"2006","journal-title":"Clin. Pharmcokinet."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222000725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222000725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:38:41Z","timestamp":1781764721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222000725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":41,"alternative-id":["S0753332222000725"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112684","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant women","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112684"}}